IQVIA (NYSE:IQV) Stock: Insider Eric Sherbet Sells 4,446 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider Eric Sherbet sold 4,446 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $278.83, for a total value of $1,239,678.18. Following the completion of the sale, the insider directly owned 24,989 shares of the company’s stock, valued at approximately $6,967,682.87. This trade represents a 15.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

IQVIA Price Performance

Shares of NYSE IQV opened at $265.44 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $284.50. The firm has a market capitalization of $43.74 billion, a P/E ratio of 32.25, a PEG ratio of 2.41 and a beta of 1.16. The company’s fifty day moving average is $267.55 and its two-hundred day moving average is $211.88.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. The business had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The business’s revenue was up 8.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on IQV. BMO Capital Markets lifted their price target on shares of IQVIA from $270.00 to $305.00 in a research report on Monday, October 19th. JPMorgan Chase & Co. upped their price target on IQVIA from $295.00 to $325.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Royal Bank Of Canada raised their price objective on IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. Finally, Jefferies Financial Group boosted their target price on IQVIA from $220.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $294.21.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently added to or reduced their stakes in the business. Compass Financial Management LLC boosted its position in IQVIA by 31.9% during the 3rd quarter. Compass Financial Management LLC now owns 157 shares of the medical research company’s stock worth $42,000 after acquiring an additional 38 shares during the period. North Dakota State Investment Board increased its holdings in shares of IQVIA by 0.8% in the 3rd quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company’s stock valued at $1,361,000 after purchasing an additional 40 shares during the period. Boston Trust Walden Corp increased its holdings in shares of IQVIA by 1.9% in the 3rd quarter. Boston Trust Walden Corp now owns 2,650 shares of the medical research company’s stock valued at $712,000 after purchasing an additional 50 shares during the period. Apella Capital LLC lifted its position in shares of IQVIA by 4.7% in the third quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock worth $319,000 after purchasing an additional 55 shares in the last quarter. Finally, Brighton Jones LLC lifted its position in shares of IQVIA by 0.7% in the third quarter. Brighton Jones LLC now owns 8,151 shares of the medical research company’s stock worth $2,191,000 after purchasing an additional 58 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.